• Investors
  • About us
  • Innovation and Technology
  • News
  • Contact & Quotation Request
  • Careers
Logo polypeptidelogo polypeptide group 2logo polypeptide groupLogo polypeptide
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial Products at PolyPeptide
    • Late Stage Development
    • Process Development and Optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial Products at PolyPeptide
    • Late Stage Development
    • Process Development and Optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Home
  • News
  • Ad hoc announcements pursuant to Art. 53 LR
  • PolyPeptide achieves strong profitable growth in 2021

PolyPeptide achieves strong profitable growth in 2021

15 March 2022
Ad hoc announcements pursuant to Art. 53 LR

Media Release – ad hoc announcement pursuant to Art. 53 LR

 

PolyPeptide achieves strong profitable growth in 2021

Zug, 15 March 2022 – PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the financial year 2021:

  • Revenue growth of 26.5% year-over-year to EUR 282.1 million, driven by custom projects in phase III of clinical development, including a substantial contribution from Novavax
  • Adjusted EBITDA up 42.4% to EUR 88.2 million; adjusted EBITDA margin of 31.3%, up 3.5 percentage points
  • Capital expenditures of EUR 76.7 million or 27.2% of revenue, reflecting accelerated capital deployment
  • Result for the year up 50.8% to EUR 47.3 million with basic EPS of EUR 1.47
  • CHF 0.30 per share as cash distribution to be proposed to AGM 2022
  • For 2022, PolyPeptide targets revenue growth of 12-14% with an adjusted EBITDA margin of around 30%
    and capital expenditures of over 25% of revenue
  • Audio webcast and telephone conference will take place today at 9.30am CET (details see page 4)

 Raymond De Vré, Chief Executive Officer of PolyPeptide, commented:

“We delivered strong sales growth of over 25% with a consistently high delivery performance in what was an exceptional year for PolyPeptide, also completing the IPO back in April 2021. Our results reflect well on PolyPeptide’s technical capabilities, execution mindset and customer focus. We remain committed to long-term relationships, as we partner with our customers on the develop­ment and commercialization of their therapeutic products – in peptides and increasingly also in oligonucleotides. I look forward to continuing to work with our customers and in doing so, to contribute to the health of millions of patients around the world.”

[…]

Download PDF

Back to news

Polypeptide Group

INFO

INVESTORS
CORPORATE NEWS
OUR STORIES
ABOUT US
MEDIA

CONTACT

CONTACT US
QUOTATION REQUEST
CAREERS

SOCIALS

LINKEDIN
FACEBOOK
TWITTER
YOUTUBE
© Confidentiality 2021 PolyPeptide Group • Cookie management • Personal data • Sitemap

ACTH (1-39) Porcine

Atosiban

Calcitonin

Carbetocin

Deslorelin

Desmopressin

Exenatide

Felypressin

Leuprolide

Liraglutide

Octreotide

PTH (1-34) Teriparatide

Semaglutide

Somatostatin

Triptorelin

Vasopressin, 8-L-Arginine

      By clicking “Accept”, you consent to the use of ALL the cookies on our website . However you may visit Cookie Settings to provide a controlled consent.
      Cookie settingsACCEPT
      Privacy & Cookies Policy

      Privacy Overview

      You can enable or disable your consent for each category of cookie.

      More information on the collection of personal data
      Necessary
      Always Enabled

      The necessary cookies help to make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

      Advertisement

      Marketing cookies are used to track visitors through websites. The goal is to display ads that are relevant and interesting to the individual user and therefore more valuable to third-party publishers and advertisers.

      Analytics

      Statistical cookies help website owners, through the anonymous collection and communication of information, to understand how visitors interact with websites.

      Performance

      Preferences cookies allow a website to retain information that changes the way the site behaves or displays, such as your preferred language or the region in which you are located.

      Save & Accept